ESR1 and breast carcinoma: The benefit of integrating the high-throughput genomic analysis of clinical specimens and relative epidemiological research, systematic studies of RBPs in one specific type or subtype of cancer will be more helpful to identify the exclusive biomarkers and potential therapeutic targets in one restrictive type of cancer, such as the ER-signaling pathway has been applied as the major therapeutic target in Luminal-like breast cancer, but is inefficient in basal-like breast cancer.